Despite sparse high-grade evidence, it was shown that PSMA-PET imaging had influence on radiotherapy treatment in more than 48% of high risk patients (treatment-naïve and recurrent prostate cancer) [6]. This evidence concerns the gene FOLH1 and prostate cancer.